Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

OLANZAPINE FOR SYSTEM SUITABILITY CRS (10 MG)

OLANZAPINE FOR SYSTEM SUITABILITY CRS (10 MG)

132539-06-1

DISCOVER
GLUCOSAMINE FOR SYSTEM SUITABILITY CRS (3 MG)

GLUCOSAMINE FOR SYSTEM SUITABILITY CRS (3 MG)

66-84-2

DISCOVER
LEVOTHYROXINE FOR PEAK IDENTIFICATION CRS (10 MG)

LEVOTHYROXINE FOR PEAK IDENTIFICATION CRS (10 MG)

25416-65-3

DISCOVER
HOMATROPINE METHYLBROMIDE FORSYSTEM SUITABILITY CRS (5 MG)

HOMATROPINE METHYLBROMIDE FORSYSTEM SUITABILITY CRS (5 MG)

80-49-9

DISCOVER
FUSIDIC ACID IMPURITY MIXTURECRS (0.048 MG)

FUSIDIC ACID IMPURITY MIXTURECRS (0.048 MG)

NA

DISCOVER
ANGELICA PUBESCENS ROOT HRS (500 MG)

ANGELICA PUBESCENS ROOT HRS (500 MG)

NA

DISCOVER
ANGELICA DAHURICA ROOT HRS (160 MG)

ANGELICA DAHURICA ROOT HRS (160 MG)

NA

DISCOVER
CANDESARTAN CILEXETIL FOR PEAK IDENTIFICATION CRS (10 MG)

CANDESARTAN CILEXETIL FOR PEAK IDENTIFICATION CRS (10 MG)

145040-37-5

DISCOVER
CANDESARTAN CILEXETIL CRS (60MG)

CANDESARTAN CILEXETIL CRS (60MG)

145040-37-5

DISCOVER
CANDESARTAN CILEXETIL FOR SYSTEM SUITABILITY CRS (10 MG)

CANDESARTAN CILEXETIL FOR SYSTEM SUITABILITY CRS (10 MG)

145040-37-5

DISCOVER
CYPROTERONE ACETATE FOR PEAK IDENTIFICATION CRS (15 MG)

CYPROTERONE ACETATE FOR PEAK IDENTIFICATION CRS (15 MG)

427-51-0

DISCOVER
GLYCEROL FORMAL CRS (20 MG)

GLYCEROL FORMAL CRS (20 MG)

4740-78-7

DISCOVER